Your browser doesn't support javascript.
loading
AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan).
Winzely, Maximilian; Jouppila, Annukka; Ramer, Georg; Lux, Laurin; Lendl, Bernhard; Barreiro, Karina; Lassila, Riitta; Friedbacher, Gernot.
Affiliation
  • Winzely M; Institute of Chemical Technologies and Analytics, Vienna University of Technology, Getreidemarkt 9/164, 1060, Wien, Austria.
  • Jouppila A; Helsinki University Hospital, Clinical Research Institute, Helsinki, Finland.
  • Ramer G; Faculty of Medicine, Research Program in Systems Oncology, Helsinki University, Helsinki, Finland.
  • Lux L; Institute of Chemical Technologies and Analytics, Vienna University of Technology, Getreidemarkt 9/164, 1060, Wien, Austria.
  • Lendl B; Institute of Chemical Technologies and Analytics, Vienna University of Technology, Getreidemarkt 9/164, 1060, Wien, Austria.
  • Barreiro K; Institute of Chemical Technologies and Analytics, Vienna University of Technology, Getreidemarkt 9/164, 1060, Wien, Austria.
  • Lassila R; Institute for Molecular Medicine Finland, Helsinki, Finland.
  • Friedbacher G; Helsinki University Hospital, Clinical Research Institute, Helsinki, Finland.
Anal Bioanal Chem ; 414(2): 1029-1038, 2022 Jan.
Article in En | MEDLINE | ID: mdl-34773471
Antiplatelet and anticoagulant drugs are classified antithrombotic agents with the purpose to reduce blood clot formation. For a successful treatment of many known complex cardiovascular diseases driven by platelet and/or coagulation activity, the need of more than one antithrombotic agent is inevitable. However, combining drugs with different mechanisms of action enhances risk of bleeding. Dual anticoagulant and antiplatelet (APAC), a novel semisynthetic antithrombotic molecule, provides both anticoagulant and antiplatelet properties in preclinical studies. APAC is entering clinical studies with this new exciting approach to manage cardiovascular diseases. For a better understanding of the biological function of APAC, comprehensive knowledge of its structure is essential. In this study, atomic force microscopy (AFM) was used to characterize APAC according to its structure and to investigate the molecular interaction of APAC with von Willebrand factor (VWF), since specific binding of APAC to VWF could reduce platelet accumulation at vascular injury sites. By the optimization of drop-casting experiments, we were able to determine the volume of an individual APAC molecule at around 600 nm3, and confirm that APAC forms multimers, especially dimers and trimers under the experimental conditions. By studying the drop-casting behavior of APAC and VWF individually, we depictured their interaction by using an indirect approach. Moreover, in vitro and in vivo conducted experiments in pigs supported the AFM results further. Finally, the successful adsorption of APAC to a flat gold surface was confirmed by using photothermal-induced resonance, whereby attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR) served as a reference method.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proteoglycans / Platelet Aggregation Inhibitors / Heparin / Microscopy, Atomic Force / Anticoagulants Limits: Humans Language: En Journal: Anal Bioanal Chem Year: 2022 Document type: Article Affiliation country: Austria Country of publication: Alemania

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proteoglycans / Platelet Aggregation Inhibitors / Heparin / Microscopy, Atomic Force / Anticoagulants Limits: Humans Language: En Journal: Anal Bioanal Chem Year: 2022 Document type: Article Affiliation country: Austria Country of publication: Alemania